Cascadian Therapeuti
Cascadian Therapeutics Announces 2018 Outlook and Recent Progress
January 04, 2018 08:30 ET | Cascadian Therapeutics, Inc.
SEATTLE, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced an overview of recent progress for tucatinib, an...
Cascadian Therapeuti
Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency
January 02, 2018 08:30 ET | Cascadian Therapeutics, Inc.
SEATTLE, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it received a product-specific pediatric...
Cascadian Therapeuti
Cascadian Therapeutics Added to the Nasdaq Biotechnology Index
December 13, 2017 08:35 ET | Cascadian Therapeutics, Inc.
SEATTLE, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (Nasdaq:CASC), a clinical-stage biopharmaceutical company, today announced that it has been selected for addition to the...
Prolonged Progressio
Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer
December 07, 2017 16:05 ET | Cascadian Therapeutics, Inc.
SAN ANTONIO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that tucatinib in combination with standard of...
Cascadian Therapeuti
Cascadian Therapeutics Reports Third Quarter 2017 Financial Results
November 08, 2017 16:01 ET | Cascadian Therapeutics, Inc.
SEATTLE, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended...
Cascadian Therapeuti
Cascadian Therapeutics to Report Third Quarter 2017 Financial Results on November 8, 2017
November 01, 2017 09:19 ET | Cascadian Therapeutics, Inc.
SEATTLE, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter financial...
Cascadian Therapeutics
Cascadian Therapeutics to Participate in Panel Discussions at Two Conferences in November
October 24, 2017 08:05 ET | Cascadian Therapeutics, Inc.
SEATTLE, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Scott D. Myers, President and Chief Executive...
Cascadian Therapeuti
Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ Metastatic Colorectal Cancer
September 27, 2017 07:00 ET | Cascadian Therapeutics, Inc.
SEATTLE, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA")...
Cascadian Therapeuti
Cascadian Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
September 20, 2017 09:00 ET | Cascadian Therapeutics, Inc.
SEATTLE, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that management will present at the Cantor...
Tucatinib Data in Mu
Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress
September 11, 2017 06:00 ET | Cascadian Therapeutics, Inc.
Results from Pooled Analysis Support the Potential Utility of Tucatinib for Patients with HER2+ Metastatic Breast Cancer with Brain Metastases Data from Nonclinical Models Support Evaluation of...